WebFeb 6, 2024 · The company changed its name to Quince, and its focus to bone disease. In January 2024, Quince put out word that it had sold Cortexyme’s legacy small molecule protease inhibitor portfolio to Lighthouse Pharmaceuticals, a company co-founded by a former Cortexyme CEO (press release). For all trials of atuzaginstat, see clinicaltrials.gov. WebJan 27, 2024 · Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals. January 27, 2024 - 8:00 am. SOUTH SAN …
Quince Therapeutics Completes the Sale of Legacy Protease …
WebLighthouse Pharmaceuticals 20 followers on LinkedIn. Precision medicine for major unmet medical needs WebJan 27, 2024 · Quince Therapeutics, a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced the sale of the company’s legacy small molecule protease inhibitor portfolio, including COR588, COR388, COR852, and COR803, pursuant to an asset purchase agreement with Lighthouse … magnolias on main springboro ohio
Nine world-leading smart factories identified by World Economic …
WebLIGHTHOUSE Instruments headspace gas ingress is a deterministic USP 1207 Container Closure Integrity Testing method meeting the requirements of EU GMP Annex 1. ... Certain sterile pharmaceutical products require deep cold storage at dry ice (-80°C) or even cryogenic (−196°C) temperatures to maintain their stability and activity. ... WebLighthouse enables pharmaceutical companies to improve quality and reduce errors, time, and cost when preparing regulatory submissions for approval. [email protected] +1 … WebLIGHTHOUSE has a proven history manufacturing a range of equipment and providing services to support your sterile product fill and finish operations. Keeping sterile product … nyu hospitalist scholar program